Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept
study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase
adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of
APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical
resolution of EKC (objective and subjective assessments), presence of opacities, visual
acuity and frequency of second eye infections, and to assess the safety and tolerability of
APD-209 Eye drops in EKC infected eyes.